Clinical Use of N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) in Diagnosing Acute Heart Failure in Emergency Settings: A Systematic Review

Acute heart failure (AHF) is a common emergency department presentation where rapid and accurate diagnosis is challenging. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a widely used biomarker for AHF, but uncertainty remains regarding optimal cut-offs and performance across patient subgroups. This systematic review evaluates the diagnostic utility of NT-proBNP for AHF in emergency settings. A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using PubMed, Embase, Scopus, and Web of Science (January 2021-April 2026). Eligible studies enrolled adults with suspected AHF in emergency settings, used NT-proBNP as the index test, and reported diagnostic accuracy outcomes. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. A narrative synthesis was performed. Eight studies were included. Across prospective emergency department studies, an NT-proBNP threshold of <300 pg/mL demonstrated strong rule-out performance, with reported sensitivities ranging from 96% to approximately 99% and negative predictive values ranging from 94.8% to 95%, depending on the study population and reference standard. Age-adjusted cut-offs (450/900/1800 pg/mL) produced rule-in specificities of 61-87%. Diagnostic accuracy was significantly reduced in patients with atrial fibrillation (AF), congenital heart disease (CHD), and heart failure with preserved ejection fraction (HFpEF). Five studies had low risk of bias, while three had high risk. NT-proBNP is a highly effective rule-out test for AHF using a <300 pg/mL cut-off. Age-adjusted cut-offs improve rule-in specificity. Performance is attenuated in key subgroups, requiring modified interpretation. Despite some methodological limitations, current evidence strongly supports routine NT-proBNP use in emergency department patients with suspected AHF.

Authors

Publication Details

Journal
Cureus
Published
2026-06-18
DOI
https://doi.org/10.7759/cureus.111120
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical Use of N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) in Diagnosing Acute Heart Failure in Emergency Settings: A Systematic Review

M Mohamed, Lobaba Mubarak Saidahmed Ahmed, Alaa Kamal Mohamed Abdalla, Ala Bala Babiker Abdalla et al.
Cureus
Heart Failure Treatment and Management
article

Clinical Use of N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) in Diagnosing Acute Heart Failure in Emergency Settings: A Systematic Review

M Mohamed, Lobaba Mubarak Saidahmed Ahmed, Alaa Kamal Mohamed Abdalla, Ala Bala Babiker Abdalla, Ebraheem Hamzeh, Rayan Mohamedani, Sahar Isameldin Osman Eisa
article en

Abstract

Acute heart failure (AHF) is a common emergency department presentation where rapid and accurate diagnosis is challenging. N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a widely used biomarker for AHF, but uncertainty remains regarding optimal cut-offs and performance across patient subgroups. This systematic review evaluates the diagnostic utility of NT-proBNP for AHF in emergency settings. A systematic review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines using PubMed, Embase, Scopus, and Web of Science (January 2021-April 2026). Eligible studies enrolled adults with suspected AHF in emergency settings, used NT-proBNP as the index test, and reported diagnostic accuracy outcomes. Risk of bias was assessed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. A narrative synthesis was performed. Eight studies were included. Across prospective emergency department studies, an NT-proBNP threshold of <300 pg/mL demonstrated strong rule-out performance, with reported sensitivities ranging from 96% to approximately 99% and negative predictive values ranging from 94.8% to 95%, depending on the study population and reference standard. Age-adjusted cut-offs (450/900/1800 pg/mL) produced rule-in specificities of 61-87%. Diagnostic accuracy was significantly reduced in patients with atrial fibrillation (AF), congenital heart disease (CHD), and heart failure with preserved ejection fraction (HFpEF). Five studies had low risk of bias, while three had high risk. NT-proBNP is a highly effective rule-out test for AHF using a <300 pg/mL cut-off. Age-adjusted cut-offs improve rule-in specificity. Performance is attenuated in key subgroups, requiring modified interpretation. Despite some methodological limitations, current evidence strongly supports routine NT-proBNP use in emergency department patients with suspected AHF.

Cureus
Good health and well-being
Openalex Percentile: Top 7%
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Clinical Use of N-terminal Pro-B-Type Natriuretic Peptide (NT-proBNP) in Diagnosing Acute Heart Failure in Emergency Settings: A Systematic Review — M Mohamed, Lobaba Mubarak Saidahmed Ahmed, et al. · Cureus (2026) | TGRS Research Map | TGRS